| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
iTonic Holdings Ltd$0.32
0 (0%)
Market Cap
5.30 M
EPS
-0.32
P/E Ratio
-
Value Trade
15.30 K
0 %
Week
3.67 %
1 Month
-16.38 %
3 Month
-46.38 %
6 Month
-91.73 %
5 Year
-91.73 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
60.13 K
52 Week Range
0.25 - 32
% held by Insiders
51.4 %
% held by Institutions
0.57 %
Enterprise Value
4.52 M
Total Shares
9.38 M
Short %
2.12 %
Float Shares
9.32 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ITOC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
iTonic Holdings Ltd (ITOC) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
ITOC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ITOC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ITOC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ITOC Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ITOC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ITOCiTonic Holdings Ltd Granted An Extension of Additional 180-Day by Nasdaq to Regain Compliance with Minimum Bid Price Rule
iTonic Holdings Ltd has been granted an additional 180 days by Nasdaq to meet the minimum bid price requirement. This extension will give the company until October 19, 2026, to comply, following the expiration of the initial compliance period on April 20, 2026. If compliance is not achieved, Nasdaq will notify the company of potential delisting of its Class A ordinary shares. The company specializes in healthcare solutions, particularly in cancer treatment technologies.
Read more →ITOCPheton Holdings Ltd Announces Corporate Name Change and Stock Ticker Symbol Change
Pheton Holdings Ltd announced a corporate name change to iTonic Holdings Ltd and a new stock ticker symbol "ITOC", effective January 16, 2026. This rebranding reflects the company's strategic shift and vision for future growth in healthcare solutions, particularly in brachytherapy. Trading under the old ticker symbol "PTHL" will cease as it adopts the new symbol on the Nasdaq Capital Market. The change is part of the company’s commitment to establishing a new standard of care in cancer treatment.
Read more →ITOCPHETON HOLDINGS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS CONTENTS PAGE(S) UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE S
Pheton Holdings Ltd has released its unaudited interim condensed consolidated financial statements, showing a significant net loss of $2,037,496 for the first six months of 2025. The company's cash and cash equivalents decreased drastically from $6,159,823 at the end of 2024 to $1,809,154 by mid-2025. Additionally, operating expenses surged, adversely impacting the company's financial stability. These negative trends raise concerns about the company's ongoing viability and profitability.
Read more →ITOCPheton Holdings Ltd ( incorporated in the Cayman Islands with limited liability) (NASDAQ: PTHL) NOTICE AND PROXY STATEMENT OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE is hereby given that an Annual General Meeting o
Pheton Holdings Ltd has announced its Annual General Meeting on December 19, 2025. Key resolutions include the re-election of several directors and the proposal to change the company's name to iTonic Holdings Ltd, along with a potential change of its NASDAQ ticker to ITOC. Shareholders will also consider the consolidation of shares, which could enhance value but may cause some confusion. The meeting highlights the company's commitment to solid leadership and strategic growth.
Read more →ITOCPheton Holdings Ltd Issues Statements Addressing Recent Market Activity and Misleading Rumors
Pheton Holdings Ltd has issued statements responding to recent market volatility linked to false rumors of a potential acquisition by Gilead Sciences. The company firmly denies any involvement in stock price manipulation and assures that it has had no contact with Gilead. In light of these misleading reports, Pheton is committed to transparency and plans to engage with regulatory bodies to address the situation. The management reaffirms its focus on maintaining shareholder trust and enhancing corporate governance.
Read more →ITOCPheton Holdings Ltd Results for the Six Months Ended
Pheton Holdings Ltd reported a significant decline in financial performance for the six months ended June 30, 2024, with total revenue falling by 21.1% to $210,488. The company faced a considerable increase in net loss, which reached $285,132, attributed to a drop in average contract prices and rising operating costs linked to professional service fees. Although there was a notable increase in sales of Medical Auxiliary Supplies, the decline in FTTPS sales revenue heavily impacted overall profitability. The company's operating expenses rose by 69% compared to the same period last year, reflecting ongoing challenges in the business environment.
Read more →ITOCPheton Holdings Ltd Announces Pricing of Initial Public Offering
Pheton Holdings Ltd has announced the pricing of its initial public offering, with 2,250,000 Class A ordinary shares available at $4.00 each. The total gross proceeds are expected to reach $9 million before expenses. The shares will start trading on the Nasdaq Capital Market under the ticker symbol 'PTHL' on September 5, 2024. The offering is closing on September 6, 2024, pending customary conditions.
Read more →Competitive Position
How ITOC ranks across every disease it competes inCompetitive Position is a premium feature
See how ITOC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial